H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report) today and set a price target of $35.00. The company’s shares closed yesterday at $12.12.
According to TipRanks, Ramakanth is an analyst with an average return of -17.8% and a 26.05% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoGen, Surgalign Holdings, and MiMedx Group.
Janux Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $29.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on Janux Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $17.46 million. In comparison, last year the company had a GAAP net loss of $13.41 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Read More on JANX:
